Findings from the VITAL trial suggest that vitamin D supplementation, with or without omega-3 fatty acids, may warrant further investigation as a strategy to reduce the risk for autoimmune diseases including rheumatoid arthritis and polymyalgia rheumatica.

Twelve weeks of high-dose vitamin D supplementation does not improve pain levels for women with fibromyalgia, research suggests.

Vitamin D and marine omega-3 fatty acid supplements are unlikely to improve chronic knee pain associated with osteoarthritis, suggests an analysis of the randomized VITAL trial.

Vitamin D intake is inversely associated with cartilage degeneration among patients with osteoarthritis, and supplementation may have a protective effect, suggests an analysis of data from the Osteoarthritis Initiative.

The use of vitamin D supplements for maintaining or improving musculoskeletal health is not warranted, suggest the findings of an updated systematic review and meta-analysis.

The use of vitamin D supplements for maintaining or improving musculoskeletal health is not warranted, suggest the findings of an updated systematic review and meta-analysis.

In this review, Finch et al summarize and evaluate the current literature relating to vitamin D and juvenile idiopathic arthritis [ read more ]. Finch SL, Rosenberg AM, Vatanparast H. Pediatr Rheumatol 2018; 16: 34. doi: 10.1186/s12969-018-0250-0

Low vitamin D levels are associated with a high risk for end-stage renal disease, thrombosis, and elevated cholesterol in patients with systemic lupus erythematosus, pointing to multiple benefits of supplementation, findings indicate.

Indeed, she reported recent findings from Jill Hahn  and team showing that a healthy lifestyle can reduce the risk for RA in women by up to a third and the VITAL trial  in which vitamin D, with or without omega-3 fatty acid supplementation, was found to reduce incident RA in at-risk individuals.

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

3–9 November: Keep up with the latest news and interviews from the conference.

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

How will the FAST trial results impact regulatory guidance & clinical practice?

However, just 46.6% of participants reported being prescribed calcium and vitamin D at baseline, while only 4.5% of those aged less than 65 years and 21.6% of those aged 65 years or older were prescribed medications such as bisphosphonates, hormone replacement therapy, or strontium.

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.